Why Is FIRST TRACKS BIOTHER (TRAX) Stock Up Today?

By the Top Tier Newswire AI Desk · October 13, 2026 at 8:31 AM ET · reviewed against 15 wire stories

FIRST TRACKS BIOTHER (TRAX) is up +6.91% in the latest session. Our newswire has captured 15 stories on TRAX across 9 sources in the last 36 hours, with AI sentiment reading bullish (avg 66/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

First Tracks Biotherapeutics shares rose 6.91% to $34.05, driven by positive top-line data from Cohort 1 of its global Phase 1b trial for ANB033 in celiac disease. The stock also received upgraded price targets from two major banks following the release of the trial results.

What Happened

First Tracks Biotherapeutics announced it will release top-line data from Cohort 1 of its Phase 1b trial of ANB033, a treatment targeting celiac disease. The company scheduled an investor webcast for 8:30 a.m. ET on October 12, 2026, to discuss the findings. The results were described as impressive, prompting a significant surge in the stock price.

In response to the data, Canaccord raised its price target for TRAX to $60 from $50. Wells Fargo also increased its price target to $70 from $62. Analysts noted that while the initial cohort results are promising, further validation is required for Cohort 2. The stock is primarily driven by the performance of ANB033, with additional trials planned for 2027.

What The Data Shows

The company has a market capitalization of $1.1 billion and remains unprofitable, with a trailing twelve-month EPS of -4.53. The 52-week trading range for the stock is $14.72 to $49.91. Over the last 8 sessions, the stock moved 0.4%, rising from $33.92 to $34.05.

Intraday activity showed the stock opened at $34.05, with a session high of $34.06 at 8:30 AM ET and a session low of $34.05 at 8:00 AM ET. Volume so far is 0.0 million shares, which is 0.0 times the 3-month daily average. The 52-week tape recorded one fresh 52-week high and 15 fresh 52-week lows on October 12, 2026. Recent insider filings show zero buys and one sell totaling $1.8 million in the last 90 days, with the most recent transaction by director Ware J. Anthony on September 4, 2026.

What To Watch

Investors will monitor the upcoming investor webcast scheduled for October 12, 2026, where the company will provide further details on the ANB033 trial data. Coverage from 15 stories across 9 sources in the last 36 hours indicates heightened attention on the stock's performance following the initial data release.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

TRAX by the numbers

Last: $34.05Session: +6.91%7 sessions: +0.38%Coverage: 15 stories / 9 sourcesAI sentiment: 66/100 (bullish)Mkt cap: $1.1B52w: $14.72 to $49.91

TRAX · today's session (5-min) · -6.98% vs prior close · updated 3:24 PM ET

AI sentiment, last 36h · averaged over 15 stories · 66/100 bullish

The headlines behind the move

Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline

7h agoInvesting.com Analyst RatingsBULLISH 64Analyst

Canaccord raises First Tracks Biotherapeutics price target on trial data

8h agoSeeking AlphaBULLISH 58Analyst

First Tracks: ANB033 Delivers, But Cohort 2 Must Follow Through

First Tracks Biotherapeutics is primarily driven by ANB033, targeting celiac disease with promising Phase 1b Cohort 1 results. See why I rate TRAX stock a hold.

8h agoThe FlyBULLISH 64Analyst

First Tracks Biotherapeutics price target raised to $60 from $50 at Canaccord

21h agoThe FlyBULLISH 63Analyst

First Tracks Biotherapeutics price target raised to $70 from $62 at Wells Fargo

1d agoMarketChameleonBULLISH 63Product/PR

TRAX jumps ahead of Oct. 12 webcast as First Tracks tees up Phase 1b ANB033 celiac data

First Tracks Biotherapeutics (TRAX) said it will release top-line data from Cohort 1 of its global Phase 1b trial of ANB033 in celiac disease on Oct. 12, 2026, followed by an 8:30 a.m. ET investor webcast. The company described Cohort 1 as a gluten-challenge study assessing prevention of mucosal damage, setting a clear near-term catalyst for investors watching the stock’s move during market hours.

1d agoInvestors.comBULLISH 74Product/PR

Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed More Than 25%

First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged.

1d agoInvestorsHubBULLISH 74Product/PR

First Tracks Biotherapeutics Shares Jump 20% After Positive Phase 1b Celiac Disease Trial Results

First Tracks Biotherapeutics shares surge 20% after ANB033 delivers positive Phase 1b celiac disease results, with further trials planned for 2027.

1d agoThe FlyBULLISH 56Product/PR

First Tracks Biotherapeutics reports results from Cohort 1 of ANB033 trial

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on TRAX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier TRAX move explainers: 2026-10-13